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ABSTRACT	 	Photosensitivity	 reactions	due	 to	pyrazinamide	 are	 rare.	 In	 this	 report,	 a	 case	of	 pyrazinamide	 induced	photodermatitis	 has	 been	 reported	 in	 a	 patient	 who	 is	 one	 anti-tuberculosis	 treatment.	 The	 patient	developed	 rashes	 with	 burning	 sensation	 which	 are	 worsened	 on	 exposure	 to	 sun.	 These	 rashes	 had	developed	since	5	days	 following	15	days	of	 start	of	 anti-tubercular	drugs.	Thus	 these	kinds	of	 adverse	reactions	can	be	prevented	on	early	detection	and	reporting	these	can	help	in	decrease	the	morbidity	rate	of	tuberculosis	with	use	of	pyrazinamide	in	the	treatment	regimens.	
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INTRODUCTION	Tuberculosis	(TB)	is	a	communicable	disease	caused	by	bacteria	 (Mycobacterium	 tuberculum)	 that	most	often	affect	lungs.	TB	still	remains	a	worldwide	public	health	problem	in	every	part	of	the	world.	According	to	WHO,	the	largest	number	of	new	cases	occurred	in	the	South-East	and	western	Pacific	regions	 in	2017,	was	62%	of	new	cases,	followed	by	the	African	region,	with	 25%	 of	 new	 cases	 and	 87%	 of	 new	 TB	 cases	occurred	 in	 the	30	high	TB	burden	countries.	Eight	countries	 accounted	 for	 two	 thirds	 of	 the	 new	 TB	cases:	 India,	China,	 Indonesia,	 the	Philippines,	Paki-stan,	Nigeria,	Bangladesh	and	South	Africa	[1].	Pyrazinamide	(PZA)	forms	an	integral	part	of	most	of	the	short	course	regimens,	 included	 in	all	 the	 three	
categories	of	DOTS	[2].	It	is	usually	bacteriostatic,	but	can	be	bactericidal	on	actively	replicating	tuberculo-sis	bacteria.	The	toxic	effects	of	PZA	are	hepatitis,	ar-thralgia,	 and	 very	 rarely	 hypersensitivity	 reactions.	With	the	increasing	use	of	the	anti-tuberculosis	treat-ment	(ATT),	one	is	likely	to	encounter	hypersensitiv-ity	reactions	with	this	drug	[3].	Here,	 in	this	case	re-port	we	report	a	case	of	pyrazinamide	induced	hyper-sensitivity.	
CASE	REPORT	
 
Figure 1: Pyrazinamide induced Photodermatitis	A	38	years	old	woman	who	was	diagnosed	as	a	fresh	case	of	pulmonary	tuberculosis	and	she	was	on	anti-tuberculosis	 treatment	(ATT)	with	rifampicin	(RIF),	isoniazid	 (INH),	 ethambutol	 (E)	 and	 pyrazinamide	(PZA)	in	appropriate	doses.	However	after	15	days	of	the	 treatment,	 she	 developed	 mild	 rashes	 on	 face,	arms	 on	 exposure	 to	 sun	 (Figure 1).	 Later	 these	rashes	became	more	intense	and	severe	that	patient	rushes	 to	 the	 hospital,	 there	 the	 patient	 was	 sus-pected	to	drug	induced	hypersensitivity	reaction	and	suggested	to	stop	all	the	ATT	drugs	and	started	on	an-tibiotics,	 steroids,	 hydration	 and	 avoidance	 of	 sun-light.	After	eight	days,	the	rashes	subsided	and	ATT	drugs	were	re-introduced	one	by	other	and	steroids	were	tapered.		
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	Thus	 on	 observation	 the	 patient	was	 diagnosed	 as	PZA	induced	photodermatitis	and	PZA	was	discontin-ued	 and	 the	 patient	 was	 advised	 to	 avoid	 sunlight	wearing	mask	and	gloves	 to	protect	 face	and	hands	from	 sunlight	 and	 use	 sun	 block	 creams.	 After	 3	months	the	patient	recovered.	
DISCUSSION	Photodermatitis	is	the	abnormal	chemically	induced	reaction	of	 the	skin	which	develops	 itchy	rashes	on	exposed	 skin	 to	 sunlight	 [5].	 Symptoms	 usually	 ap-pears	on	the	sun	exposed	areas	of	the	body	such	as	back	of	hands,	front	of	arms,	lower	areas	of	legs	and	face	[6].	A	diagnosis	of	drug	hypersensitivity	depends	on	 identifying	 symptoms	and	physical	 findings	 that	are	compatible	with	an	immune	drug	reaction	(Figure 
2)	[10].	There	 are	 very	 few	 reports	 showing	 PZA	 induced	rashes	in	literature	[4-6].	Allergic	skin	reactions	to	PZA	are	usually	mild	and	liable	to	occur	in	approximately	3%	of	cases	 [7].	Most	allergic	reactions	occur	within	the	 first	 four	weeks	 of	 therapy	 and	mainly	 present	with	 a	 fever	 and/or	 skin	 rash.	With	 PZA,	 It	 is	 esti-mated	that	1	in	100	persons	show	some	signs	of	pho-tosensitivity.	 Photosensitivity	 reaction	 is	 caused	 by	an	 interaction	between	 light	rays	and	a	photosensi-tizing	agent	(chromophore)	which	 is	activated	after	absorbing	the	light	ray	and	it	is	more	common	on	the	skin	due	to	natural	exposure	to	the	sun	rays	[8].		
INH	is	the	most	potent	ATD	and	RIF	has	a	better	ster-ilizing	 action	 than	 PZA.	 E	 prevents	 development	 of	drug	 resistance,	 a	 property	 also	 shared	 by	 bacteri-cidal	drug.	PZA	is	a	very	limited	agent	in	terms	of	its	
in	vitro	activity,	but	by	virtue	of	its	sterilizing	action	on	dormant	bacilli	which	are	responsible	for	relapse,	it	facilitates	reduction	in	duration	of	treatment	from	9	 to	 6	months.	 Hence	 good	 cure	 rates	 are	 possible	with	regimens	without	PZA,	provided	a	minimum	of	nine	months	of	 treatment	 is	ensured	 to	prevent	 re-lapses	[9].	
CONCLUSION	This	case	emphasizes	the	occurrence	of	photoderma-titis	consequently	upon	PZA	use,	an	adverse	reaction	that	has	been	described	with	the	usage	of	ATT	drugs.	Taking	this	case	into	consideration,	the	frequency	of	occurring	this	adverse	event	on	PZA	use	in	the	anti-tuberculosis	treatment	and	reporting	it	to	the	phar-macovigilance	(PV),	provides	a	good	sign	for	develop-ing	spontaneous	reporting	system	of	rare	cases	in	PV	centers	to	improve	patient	safety.	
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Figure 2: Algorithm for the evaluation and management of drug reaction 
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